Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss

Journal of Sexual Medicine

Volumn 8, Issue 6, 2011, Pages 1747-1753

  Irwig, Michael S ^a   Kolukula, Swapna ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

5 Alpha Reductase Inhibitor; Erectile Dysfunction; Finasteride; Libido; Propecia; Sexual Side Effects

Indexed keywords

FINASTERIDE; HORMONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HAIR LOSS; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTERVIEW; LIBIDO DISORDER; MALE; MALE SEXUAL DYSFUNCTION; NORMAL HUMAN; ORGASM DISORDER; PHYSICIAN; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL BIAS; RISK; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; STANDARDIZATION; TREATMENT DURATION;

EID: 79957924605     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02255.x     Document Type: Article

References (21)

1. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia: Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39:578-89.
2. McClellan KJ, Markham A. Finasteride: A review of its use in male pattern hair loss. Drugs 1999;57:111-26.
3. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006;55:1014-23.
4. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community based study. Clin Ther 1995;17:956-69.
5. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003;61:791-6.
6. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155:1251-9.
7. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-84.
8. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther 2000;26:25-40.
9. Sukan M, Maner F. The problems in sexual functions of vitiligo and chronic urticaria patients. J Sex Marital Ther 2007;33:55-64.
10. DeRogatis LR. Assessment of sexual function/dysfunction via patient reported outcomes. Int J Impot Res 2008;20:35-44.
11. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872-84.
12. Melcangi RC, Magnaghi V, Martini L. Steroid metabolism and effects in central and peripheral glial cells. J Neurobiol 1999;40:471-83.
13. Melcangi RC, Riva MA, Fumagalli F, Magnaghi V, Racagni G, Martini L. Effect of progesterone, testosterone and their 5 alpha-reduced metabolites on GFAP gene expression in type 1 astrocytes. Brain Res 1996;711:10-5.
14. Merck & Co.. Propecia prescribing information. West Point, PA: Merck; 1997.
15. Celotti F, Melcangi RC, Martini L. The 5 alpha-reductase in the brain: Molecular aspects and relation to brain function. Front Neuroendocrinol 1992;13:163-215.
16. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 1990;87:3640-4.
17. Schumaker M, Ghoumari A, Guennoun R, Labombarda F, Gonzalez SL, Gonzalez Deniselle MC, Massaad C, Grenier J, Rajkowski KM, Robert F, Baulieu EE, De Nicola AF. Progestins and antiprogestins: Mechanisms of action, neuroprotection and myelination. In: Kordon C, etal., ed. Hormones and the brain. Berlin: Springer-Verlag; 2005:111-54.
18. Canguven O, Burnett AL. The effect of 5 alpha-reductase inhibitors on erectile function. J Androl 2008;29:514-23.
19. Seo SI, Kim SW, Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl 1999;1:169-74.
20. Foresta C, Caretta N, Rossato M. Erectile function in elderly: Role of androgens. J Endocrinol Invest 2003;26:77-81.
21. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467-72.